The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.

AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for ...

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core ...

The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance even if the U.S.

AstraZeneca may face a fine of up to $8 million in China over suspected unpaid taxes related to the import of its breast ...

The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over ...

The FDA pushed back its decision date on Cytokinetics’ heart drug, while AstraZeneca got Phase 3 results that could help it ...

AstraZeneca CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on ...

The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...

May 2 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for uncontrolled asthma ...